For the Inventor, By the Inventor

Enter assignee name

Gaithersburg, MD, United States of America

Novavax, Inc.

USPTO Granted Patents = 65

% Expired Patents = 3.1

CIPO Patents = 4

EPO Patents = 12

Trademarks = 7

Forward Citations = 959

Loading Chart...

Loading Chart...

38 inventors (with patents filed for the assignee):

Gale Smith (44 out of 45 patents)

Peter M Pushko (32 out of 58 patents)

Michael J Massare (24 out of 26 patents)

4. Ye Liu (17 out of 32 patents)

5. Jing-Hui Tian (15 out of 23 patents)

6. Kutub Mahmood (13 out of 13 patents)

7. Yingyun Wu (12 out of 12 patents)

8. Rick Bright (11 out of 11 patents)

9. Jinyou Zhang (11 out of 11 patents)

10. Robin A Robinson (11 out of 12 patents)

11. D Craig Wright (11 out of 16 patents)

12. Bin Zhou (9 out of 9 patents)

13. Sarathi Boddapati (6 out of 7 patents)

14. Gregory M Glenn (5 out of 36 patents)

15. Erica Shane (4 out of 15 patents)

Core Competencies:

Coronavirus Vaccine

RSV F Proteins

Influenza VLPs

Vaccine Compositions

Immunogenicity

Multivalent Vaccines

Stability

Chimeric VLPs

Antiviral Activity

Lipid Vesicles

Adjuvants

Nanoparticles

65 patents: Sort by Forward Citations

1. 12691171 - CORONAVIRUS VACCINE FORMULATIONS (2026-07-28),

2. 12491241 - CORONAVIRUS VACCINE FORMULATIONS (2025-12-09),

3. 12472246 - CORONAVIRUS VACCINE FORMULATIONS (2025-11-18),

4. 12357684 - Modified RSV F proteins and methods of their use (2025-07-15),

5. 12257297 - Vaccine compositions having improved stability and immunogenicity (2025-03-25),

6. 11938179 - Methods and compositions for inducing immune responses against (2024-03-26),

7. 11896664 - Corona virus vaccine formulations (2024-02-13),

8. 11896662 - Multivalent influenza nanoparticle vaccines (2024-02-13),

9. 11541112 - Coronavirus vaccine formulations (2023-01-03),

10. 11446374 - Modified RSV F proteins and methods of their use (2022-09-20),

11. 11364294 - Vaccine compositions having improved stability and immunogenicity (2022-06-21),

12. 11278612 - Multivalent influenza nanoparticle vaccines (2022-03-22),

13. 11253586 - Coronavirus vaccine formulations (2022-02-22),

14. 11253585 - Vaccine compositions having improved stability and immunogenicity (2022-02-22),

15. 11123419 - Methods and compositions for inducing immune responses against Clostridium difficile (2021-09-21),

Novavax, Inc. is an American biotechnology company that specializes in the development of vaccines. Their innovative vaccine platform utilizes advanced technology to create novel vaccines against various infectious diseases. Novavax's focus includes vaccines for respiratory syncytial virus (RSV), influenza, Ebola, and now the COVID-19 virus. The company strives to address global health challenges through its cutting-edge research and development efforts.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

65 Patents

#4 in Gaithersburg, MD

#51 in Maryland

#5,601 in US

#11,312 in the World

Gaithersburg, MD, United States of America

Novavax, Inc.

Forward Citations = 959

38 inventors:

Gale Smith (44 out of 45 patents)

Peter M Pushko (32 out of 58 patents)

Michael J Massare (24 out of 26 patents)

4. Ye Liu (17 out of 32 patents)

5. Jing-Hui Tian (15 out of 23 patents)

Please report any incorrect information to [email protected]

Loading…